Screening, monitoring, and treatment of albuminuria: Public health perspectives

被引:190
作者
de Jong, Paul E.
Curhan, Gary C.
机构
[1] Univ Groningen, Med Ctr, Div Nephrol, Dept Med, NL-9713 GZ Groningen, Netherlands
[2] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2006年 / 17卷 / 08期
关键词
D O I
10.1681/ASN.2006010097
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Microalbuminuria is an early sign of progressive cardiovascular and renal disease in individuals with and without diabetes. Despite compelling data, at present only a minority of patients with diabetes and rarely individuals without diabetes are screened for albuminuria in a systematic way. All of the criteria to implement systematic albuminuria screening are fulfilled in diabetes, and most are nearly fulfilled for microalbuminuria screening in individuals without diabetes. Because of the growing evidence that treatment of microalbuminuria in individuals without diabetes may offer A cost-effective benefit to prevent cardiovascular disease, nephrologists and other health care providers should pay more attention to the early detection and subsequent treatment of individuals with microalbuminuria.
引用
收藏
页码:2120 / 2126
页数:7
相关论文
共 51 条
[21]   Cost-effectiveness of screening for proteinuria [J].
Gansevoort, RT ;
de Jong, PE ;
Postma, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (12) :1442-1443
[22]   Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population [J].
Hillege, HL ;
Fidler, V ;
Diercks, GFH ;
van Gilst, WH ;
de Zeeuw, D ;
van Veldhuisen, DJ ;
Gans, ROB ;
Janssen, WMT ;
Grobbee, DE ;
de Jong, PE .
CIRCULATION, 2002, 106 (14) :1777-1782
[23]   Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity [J].
Hillege, HL ;
Janssen, WMT ;
Bak, AAA ;
Diercks, GFH ;
Grobbee, DE ;
Crijns, HJGM ;
van Gilst, WH ;
de Zeeuw, D ;
de Jong, PE .
JOURNAL OF INTERNAL MEDICINE, 2001, 249 (06) :519-526
[24]   Proteinuria and the risk of developing end-stage renal disease [J].
Iseki, K ;
Ikemiya, Y ;
Iseki, C ;
Takishita, S .
KIDNEY INTERNATIONAL, 2003, 63 (04) :1468-1474
[25]   Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition - A patient-level meta-analysis [J].
Jafar, TH ;
Stark, PC ;
Schmid, CH ;
Landa, M ;
Maschio, G ;
de Jong, PE ;
de Zeeuw, D ;
Shahinfar, S ;
Toto, R ;
Levey, AS .
ANNALS OF INTERNAL MEDICINE, 2003, 139 (04) :244-252
[26]   Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO) [J].
Levey, AS ;
Eckardt, KU ;
Tsukamoto, Y ;
Levin, A ;
Coresh, J ;
Rossert, J ;
de Zeeuw, D ;
Hostetter, TH ;
Lameire, N ;
Eknoyan, G .
KIDNEY INTERNATIONAL, 2005, 67 (06) :2089-2100
[27]   Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J].
Lewis, EJ ;
Hunsicker, LG ;
Clarke, WR ;
Berl, T ;
Pohl, MA ;
Lewis, JB ;
Ritz, E ;
Atkins, RC ;
Rohde, R ;
Raz, I .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :851-860
[28]   THE EFFECT OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITION ON DIABETIC NEPHROPATHY [J].
LEWIS, EJ ;
HUNSICKER, LG ;
BAIN, RP ;
ROHDE, RD .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (20) :1456-1462
[29]  
Mattix HJ, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341034
[30]   PREDICTION OF CLINICAL DIABETIC NEPHROPATHY IN IDDM PATIENTS - ALTERNATIVES TO MICROALBUMINURIA [J].
MOGENSEN, CE .
DIABETES, 1990, 39 (07) :761-767